SAN DIEGO, CA -- BrainCells, Inc. announced the completion of the initial closing of its series B round of venture capital, receiving $30 million.
The company is developing drugs for depression, related neuropsychiatric disorders and other central nervous system diseases.
Investors in the round included MedImmune which led the financing, Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and others.
|